Zobrazeno 1 - 10
of 114
pro vyhledávání: ''
Autor:
Daniel L. Flynn, Jarnail Singh, Bryan D. Smith, César Serrano, Alfonso García-Valverde, Anu Gupta
Publikováno v:
Molecular Cancer Therapeutics. 20:1234-1245
The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first-, second-, and third-line targeted therapies, respectively, for meta
Autor:
Xixi Cao, Jamunarani Veeraraghavan, Shunqiang Li, Martin Shea, Lanfang Qin, Ying Tan, Susan G. Hilsenbeck, Xian Wang, Xiaosong Wang, Yiheng Hu, Jin-Ah Kim, Ling Lin, Tamika Mitchell, Rachel Schiff, Chia Chia Liu, Suet Kee Loo, Matthew J. Ellis, Sanghoon Lee
Publikováno v:
Clin Cancer Res
Purpose: Endocrine resistance remains a major clinical challenge in estrogen receptor (ER)–positive breast cancer. Despite the encouraging results from clinical trials for the drugs targeting known survival signaling, relapse is still inevitable. T
Autor:
Aaron Smith, Peter Johnström, Katarina Varnäs, James Atkinson, Minghui Zhao, Nicole Strittmatter, Yumei Yan, Ryosuke Arakawa, Nicola Colclough, Annika Janefeldt, M. Raymond V. Finlay, Albert D. Windhorst, Evgeny Revunov, Natasha A. Karp, Kan Chen, Lin Zhang, Gareth Maglennon, Peter Barton, Richard J. A. Goodwin, Ana Vazquez-Romero, Magnus Schou, Akihiro Takano, Gail L. Wrigley, Darren Cross, Mikhail Kondrashov, Mohammad Mahdi Moein, Zack Cheng, Paul D. Smith, Sally J. Adua, Richard A. Ward, Lars Farde, James W.T. Yates, Joanne Wilson, Jonas Malmquist, Don X. Nguyen
Publikováno v:
Colclough, N, Chen, K, Johnstrom, P, Strittmatter, N, Yan, Y, Wrigley, G L, Schou, M, Goodwin, R, Varnas, K, Adua, S J, Zhao, M, Nguyen, D X, Maglennon, G, Barton, P, Atkinson, J, Zhang, L, Janefeldt, A, Wilson, J, Smith, A, Takano, A, Arakawa, R, Kondrashov, M, Malmquist, J, Revunov, E, Vazquez-Romero, A, Moein, M M, Windhorst, A D, Karp, N A, Finlay, R V, Ward, R A, Yates, J W T, Smith, P D, Farde, L, Cheng, Z & Cross, D A E 2021, ' Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs ', Clinical Cancer Research, vol. 27, no. 1, pp. 189-201 . https://doi.org/10.1158/1078-0432.CCR-19-1871
Clinical Cancer Research, 27(1), 189-201. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(1), 189-201. American Association for Cancer Research Inc.
Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood–brain barrier (BBB) permeability is considered desirable for incre
Autor:
Deukwoo Kwon, Nipun B. Merchant, Michelle L. Reyzer, Xizi Dai, Brent A. Willobee, Supriya Srinivasan, Siddharth Mehra, Nagaraj S. Nagathihalli, Nilesh Kashikar, Austin R. Dosch, Richard M. Caprioli
Publikováno v:
Mol Cancer Res
Lack of durable response to cytotoxic chemotherapy is a major contributor to the dismal outcomes seen in pancreatic ductal adenocarcinoma (PDAC). Extensive tumor desmoplasia and poor vascular supply are two predominant characteristics which hinder th
Autor:
Joseph Schoepfer, Pascal Furet, Jinsheng Liang, Matthew T. DiMare, William R. Sellers, Hui Qin Wang, Alan Huang, Huaixiang Hao, Angela Tam, Ralph Tiedt, Youzhen Wang, Sabrina Baltschukat, Francesco Hofmann, Hyo-eun C. Bhang, Barbara Schacher Engstler
Publikováno v:
Clinical Cancer Research. 25:3164-3175
Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical trials, both as a single agent and in combination. Here, we describe the preclinical data of capmatinib, which supported the clinical biomarker strategy for ra
Autor:
Anton Berns, Natalie Proost, Nanne Aben, Marieke van de Ven, Jan van der Vliet, Hilda de Vries, Remco Nagel, Lodewyk F. A. Wessels, Ana Teresa Avelar, Miranda Cozijnsen
Publikováno v:
Molecular Cancer Therapeutics. 18:762-770
Small cell lung cancer (SCLC) is generally regarded as very difficult to treat, mostly due to the development of metastases early in the disease and a quick relapse with resistant disease. SCLC patients initially show a good response to treatment wit
Autor:
Jasmien Cornillie, Madalina-Elena Zhai, Christoph Lengauer, Raf Sciot, Jasmien Wellens, Agnieszka Wozniak, Yemarshet K. Gebreyohannes, Ulla Vanleeuw, Maria Debiec-Rychter, Alexandra K. Gardino, Erica Evans, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 25:609-618
Purpose: Gastrointestinal stromal tumors (GIST) are commonly treated with tyrosine kinase inhibitors (TKI). The majority of patients with advanced GIST ultimately become resistant to TKI due to acquisition of secondary KIT mutations, whereas primary
Autor:
Kiyoshi Uemasu, Koichi Hasegawa, Hiroki Nagai, Hiroaki Ozasa, Hironori Yoshida, Koh Furugaki, Takashi Nomizo, Wataru Aoki, Yuto Yasuda, Shunsuke Aburaya, Hitomi Ajimizu, Toyohiro Hirai, Takahiro Tsuji, Tomoko Funazo, Yuichi Sakamori, Ryoko Okutani, Yasushi Yoshimura, Mitsuyoshi Ueda, Yoshitaka Yagi, Young Hak Kim
Publikováno v:
Molecular Cancer Research. 17:212-224
The mechanisms responsible for the development of resistance to alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, are still unclear, and few cell lines are currently available for investigating ALK-rearranged lung cancer. To
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Maicol Mancini, Moshit Lindzen, Swati Srivastava, Jair Bar, Matthew Kreitman, Donatella Romaniello, Ashish Noronha, Luigi Mazzeo, Soma Ghosh, Ilaria Marrocco, Tomer-Meir Salame, Amir Onn, Yosef Yarden
Publikováno v:
Clinical Cancer Research, vol. 24, no. 22, pp. 5610-5621
Clinical Cancer Research
Clinical Cancer Research
Purpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), no targeted treatments are available for patients with lung cancer who lose sensitivity due to new mutations or bypass mechanisms. We